PROF profoundmedical.com: Long-Term Debt to Capital Coefficient

This daily price chart for Profound Medical Corp. (PROF) is based on B2B deliveries of TULSA-PRO systems and ancillary materials to clinics, with the indicator standing at 0.06. Profound Medical Corp. (PROF) is scaling an innovative method for combating prostate cancer via MRI guidance. Effective management is controlling development costs and expanding medical insurance coverage, ensuring transparency in the product's market penetration.

This ratio determines the company's dependence on long-term borrowings relative to its equity, highlighting shareholder dilution risks in the event of a decline in market value. By analyzing the long-term debt-to-equity chart, an investor can see the extent to which Profound Medical Corp. (PROF) is capable of financing the integration of its innovations into insurance systems without critically increasing its credit load amid competition with medtech behemoths.